1. Home
  2. Directory
  3. Delaware
  4. Wilmington
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1801832829

WILLIAM JEPPE
Prescription History 1801832829
Optometrist in Wilmington, DE

NPI Status: Active since June 20, 2006

Contact Information

5301 LIMESTONE RD STE 128
WILMINGTON, DE
ZIP 19808
Phone: (302) 239-1933
Fax: (302) 239-1002

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for WILLIAM JEPPE, an active Optometrist specialist practicing in Wilmington, DE. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 118 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 71 claims alone.

Medication Index

L
N
No matching medications currently found on file.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 71
30-Day Fills 92.2
Days Supply 2,491
DE State Average Benchmarks
Peer Average Claims130.0
Peer Average 30-Day Fills266.5
Peer Average Days Supply7,739
Conservative Utilization

This provider writes prescriptions for this formulation 45.4% less frequently than the standard regional baseline metric for practitioners inside DE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $513.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.24

State Avg Cost Per Claim

$22.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Loteprednol Etabonate

Generic Formulation: Loteprednol EtabonateSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 352
DE State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills44.0
Peer Average Days Supply1,225
Conservative Utilization

This provider writes prescriptions for this formulation 34.6% less frequently than the standard regional baseline metric for practitioners inside DE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,170.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$127.68

State Avg Cost Per Claim

$250.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.

Therapeutic Applications

This medication is used to temporarily relieve seasonal allergy symptoms of the eyes such as swelling, redness, and itching. Loteprednol belongs to a class of drugs known as corticosteroids.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 35.8
Days Supply 1,074
DE State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills85.8
Peer Average Days Supply2,517
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 58.5% less volume than the regional standard for practitioners inside DE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,165.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$539.15

State Avg Cost Per Claim

$544.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 182
DE State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills35.0
Peer Average Days Supply552
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.6% less volume than the regional standard for practitioners inside DE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $128.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.91

State Avg Cost Per Claim

$13.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like WILLIAM JEPPE provides transparency into local medical care patterns within Wilmington, DE.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.